Go Pro
→ How Elon’s Empire Ends (and how to profit) (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$13.74
-1.2%		$10.49
$2.74
▼
$15.02
$4.21B1.46.11 million shs3.69 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$41.40
+2.3%		$42.91
$14.25
▼
$48.51
$4.50B0.351.24 million shs1.43 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$18.96
+2.5%		$19.09
$5.26
▼
$21.27
$4.15B1.723.20 million shs2.77 million shs
TRAX
First Tracks Biotherapeutics
$33.28
-1.9%		$41.56
$14.72
▼
$49.91
$1.19BN/A652,263 shs1.17 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-4.66%+9.96%+23.32%+71.52%+133.39%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-0.60%-1.65%-4.19%+2.33%+162.18%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
+2.44%+4.29%0.00%-0.86%+247.56%
TRAX
First Tracks Biotherapeutics
-4.29%-5.33%-17.61%+75.75%+3,391,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$13.74
-1.2%		$10.49
$2.74
▼
$15.02
$4.21B1.46.11 million shs3.69 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$41.40
+2.3%		$42.91
$14.25
▼
$48.51
$4.50B0.351.24 million shs1.43 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$18.96
+2.5%		$19.09
$5.26
▼
$21.27
$4.15B1.723.20 million shs2.77 million shs
TRAX
First Tracks Biotherapeutics
$33.28
-1.9%		$41.56
$14.72
▼
$49.91
$1.19BN/A652,263 shs1.17 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-4.66%+9.96%+23.32%+71.52%+133.39%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-0.60%-1.65%-4.19%+2.33%+162.18%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
+2.44%+4.29%0.00%-0.86%+247.56%
TRAX
First Tracks Biotherapeutics
-4.29%-5.33%-17.61%+75.75%+3,391,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.67
Moderate Buy$13.38-2.66% Downside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.82
Moderate Buy$51.3323.99% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.93
Moderate Buy$25.9236.69% Upside
TRAX
First Tracks Biotherapeutics
2.79
Moderate Buy$65.1795.81% Upside

Current Analyst Ratings Breakdown

Latest TRAX, EWTX, ABCL, and RLAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
TRAX
First Tracks Biotherapeutics
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$50.00
9/29/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$17.00
9/24/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$13.00
9/21/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $57.00
9/18/2026
TRAX
First Tracks Biotherapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$65.00
9/18/2026
TRAX
First Tracks Biotherapeutics
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$65.00
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/16/2026
TRAX
First Tracks Biotherapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/16/2026
TRAX
First Tracks Biotherapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$100.00
9/3/2026
TRAX
First Tracks Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$57.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$75.13M56.07N/AN/A$3.23 per share4.25
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.93 per shareN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$15.35M270.68N/AN/A$3.27 per share5.80
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.54N/AN/AN/A-248.83%-17.49%-12.36%11/9/2026 (Confirmed)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M-$1.85N/AN/AN/AN/A-39.01%-36.96%11/5/2026 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$276.48M-$1.57N/AN/AN/AN/A-42.27%-38.67%11/5/2026 (Estimated)
TRAX
First Tracks Biotherapeutics
N/A-$1.84N/AN/AN/AN/AN/AN/AN/A

Latest TRAX, EWTX, ABCL, and RLAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
TRAX
First Tracks Biotherapeutics
-$0.74-$0.95-$0.21-$0.95N/AN/A
8/6/2026Q2 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.4677-$0.53-$0.0623-$0.53N/AN/A
8/6/2026Q2 2026
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.3911-$0.41-$0.0189-$0.41$0.96 million$0.35 million
8/5/2026Q2 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1640-$0.18-$0.0160-$0.18$7.85 million$4.05 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
12.77
12.77
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
16.24
16.24
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
18.27
18.27
TRAX
First Tracks Biotherapeutics
N/A
14.28
14.28

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%
TRAX
First Tracks Biotherapeutics
N/A

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
21.30%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
5.04%
TRAX
First Tracks Biotherapeutics
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
562306.61 million219.53 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
127108.60 million85.47 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
192219.14 million208.10 millionOptionable
TRAX
First Tracks Biotherapeutics
10435.73 millionN/AN/A

Recent News About These Companies

First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Picked Up by Analysts at Canaccord Genuity Group
October 2 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31076707
Canaccord Genuity initiates coverage of First Tracks Biotherapeutics with a buy rating
October 1 at 7:28 AM  |  msn.comhttps://www.msn.com/en-us/news/other/canaccord-genuity-initiates-coverage-of-first-tracks-biotherapeutics-with-a-buy-rating/ar-AA2dgZvS
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Rated "Buy" in New Coverage at Canaccord Genuity Group
September 30 at 8:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-stock-rated-buy-in-new-coverage-at-canaccord-genuity-group-2026-09-30/
30,339 Shares in First Tracks Biotherapeutics $TRAX Bought by Corient Private Wealth LP
September 30 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-30339-shares-in-first-tracks-biotherapeutics-trax-bought-by-corient-private-wealth-lp-2026-09-30/
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Has Average Target Price of $66.55 According to Analysts
September 30 at 1:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067111
Der aktuelle Kurs der First Tracks Biotherapeutics Inc Aktie beträgt 34,42.
September 26, 2026  |  de.investing.comhttps://de.investing.com/equities/first-tracks-biotherapeutics
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Has Consensus Target Price of $66.55 According to Analysts
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-first-tracks-biotherapeutics-nasdaq-trax-stock-has-consensus-target-price-of-6655-according-to-analysts-2026-09-25/
State Street Corp Buys 1,512,896 Shares of First Tracks Biotherapeutics $TRAX
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-state-street-corp-buys-1512896-shares-of-first-tracks-biotherapeutics-trax-2026-09-25/
Tidal Investments LLC Makes New Investment in First Tracks Biotherapeutics $TRAX
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-tidal-investments-llc-makes-new-investment-in-first-tracks-biotherapeutics-trax-2026-09-22/
Evercore ISI Starts First Tracks Biotherapeutics (TRAX) at Outperform
September 18, 2026  |  streetinsider.comhttps://www.streetinsider.com/New+Coverage/Evercore+ISI+Starts+First+Tracks+Biotherapeutics+%28TRAX%29+at+Outperform/27077856.html
Guggenheim initiates coverage of First Tracks Biotherapeutics with buy
September 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/guggenheim-initiates-coverage-of-first-tracks-biotherapeutics-with-buy/ar-AA2cnIfO
First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Rating Upgraded by Guggenheim
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-stock-rating-upgraded-by-guggenheim-2026-09-17/
Guggenheim Starts First Tracks Biotherapeutics (TRAX) at Buy,
September 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/Analyst+Comments/Guggenheim+Starts+First+Tracks+Biotherapeutics+%28TRAX%29+at+Buy%2C/27066556.html
Why First Tracks Biotherapeutics, Inc.’s (TRAX) Stock Is Up 5.01%
September 14, 2026  |  aaii.comA
Wellington Management Group LLP Makes New $1.16 Million Investment in First Tracks Biotherapeutics $TRAX
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wellington-management-group-llp-makes-new-116-million-investment-in-first-tracks-biotherapeutics-trax-2026-09-12/
Opaleye Management Inc. Invests $1.31 Million in First Tracks Biotherapeutics $TRAX
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-opaleye-management-inc-invests-131-million-in-first-tracks-biotherapeutics-trax-2026-09-11/
J. Anthony Ware Sells 39,265 Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) Stock
September 5, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-trax-insider-buying-and-selling-2026-09-05/
First Tracks Biotherapeutics (NASDAQ:TRAX) Downgraded to "Sell" Rating by Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-nasdaq-trax-downgraded-to-sell-rating-by-wall-street-zen-2026-09-05/
First Tracks Biotherapeutics (NASDAQ:TRAX) Director Sells $1,758,286.70 in Stock
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-first-tracks-biotherapeutics-nasdaq-trax-director-sells-175828670-in-stock-2026-09-04/
First Tracks Biotherapeutics' (TRAX) Buy Rating Reiterated at HC Wainwright
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-first-tracks-biotherapeutics-trax-buy-rating-reiterated-at-hc-wainwright-2026-09-03/
First Tracks Biotherapeutics Inc (TRAX)
August 30, 2026  |  de.investing.comhttps://de.investing.com/equities/first-tracks-biotherapeutics-financial-summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$13.74 -0.17 (-1.22%)
Closing price 04:00 PM Eastern
Extended Trading
$13.83 +0.09 (+0.66%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$41.40 +0.92 (+2.27%)
Closing price 04:00 PM Eastern
Extended Trading
$41.40 0.00 (0.00%)
As of 04:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$18.96 +0.47 (+2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$18.95 -0.01 (-0.05%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

First Tracks Biotherapeutics NASDAQ:TRAX

$33.28 -0.64 (-1.89%)
Closing price 04:00 PM Eastern
Extended Trading
$33.31 +0.03 (+0.09%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas